Ahmad Masri, Cardiologist and Associate Professor of Medicine at Oregon Health and Science University (OHSU), shared on X:
“Topline results from the CARDIO-TTRansform trial Primary was not met Subgroup (monotherapy) reported nominally significant (HR 0.71) ~57% baseline tafamidis use.
Trial will be presented at ESC.”
Other articles about Cardio-Oncology on OncoDaily.